CLAIMS

1. A probe and/or therapeutic polypeptide suitable for targeting phosphatidylserine cell-surface expression both *in vitro* and *in vivo* said polypeptide comprising:

a protein S gamma-carboxyglutamic-acid (Gla) domain, and
an EGF domain,
wherein said polypeptide is fused to a proteinaceous sequence; and
wherein said polypeptide lacks a protease domain and also lacks a hormone-binding domain.

2. The polypeptide according to claim 1 comprising an EGF domain from protein S.

3. The polypeptide according to claim 2, wherein the GLA domain has the sequence shown in SEQ ID NO: 1.

4. The polypeptide according to any one of claims 1 to 3, wherein the polypeptide is 300 amino acids or less.

5. The polypeptide according to any one of claims 1 to 3, comprising SEQ ID NO: 6.

6. The polypeptide according to any one of claims 1 to 5, wherein the polypeptide further comprises an antibody Fc region.

7. A polypeptide according to any one of claims 1 to 6, for use in treatment.

8. A polypeptide according to claim 7, for use in treatment in a combination therapy.

9. Use of a polypeptide according to any one of claims 1 to 6, in the manufacture of a medicament for the treatment of cancer.

10. Use of a polypeptide according to any one of claims 1 to 6, in the manufacture of a medicament for the treatment of a viral infection.

11. Use according to claim 10, for the treatment of a viral infection selected from the group consisting of influenza, human immunodeficiency virus, dengue virus, West Nile virus, smallpox virus, respiratory syncytial virus, Korean hemorrhagic fever virus, chickenpox, varicella zoster virus, herpes simplex virus 1 or 2, Epstein-Barr virus, Marburg virus, hantavirus, yellow fever virus, hepatitis A, B, C or E, Ebola virus, human papilloma virus, rhinovirus, Coxsackie virus, polio virus, measles virus, rubella virus, rabies virus, Newcastle disease virus, rotavirus, HTLV-1 and -2.

12. Use of a polypeptide according to any one of claims 1 to 6, in the manufacture of a medicament for the treatment of hypercoagulation disorders.

13. Use according to any one of claims 1 to 6, in the manufacture of a medicament for the treatment of autoimmune and/or an inflammatory disease state.

14. Use according to claim 13, wherein the disease state is selected from the group consisting of spondyloarthropathy, ankylosing spondylitis, psoriatic arthritis, reactive arthritis, enteropathic arthritis, ulcerative colitis, Crohn's disease, irritable bowel disease, inflammatory bowel disease, rheumatoid arthritis, juvenile rheumatoid arthritis, familial Mediterranean fever, amyotrophic lateral sclerosis, Sjogren's syndrome, early arthritis, viral arthritis, multiple sclerosis, systemic lupus erythematosus, psoriasis, vasculitis, Wegener's granulomatosis, Addison's disease, alopecia, antiphospholipid syndrome, Behcet's disease, celiac disease, chronic fatigue syndrome, ulcerative colitis, type I diabetes, fibromyalgia, autoimmune gastritis, Goodpasture syndrome, Graves' disease, idiopathic thrombocytopenic purpura (ITP), myasthenia gravis, pemphigus vulgaris, primary biliary cirrhosis, rheumatic fever, sarcoidosis, scleroderma, vitiligo, vasculitis, small vessel vasculitis, hepatitis, primary biliary cirrhosis, sarcoidosis, scleroderma, graft versus host disease (acute and chronic), aplastic anemia, and cyclic neutropenia.

15. Use of a polypeptide according to any one of claims 1 to 6, in the manufacture of a medicament for the treatment of sepsis.